Brief: Cyclo Therapeutics Presents Encouraging Preliminary Safety Data From Ongoing Pivotal Phase 3 Study And Substudy For The Treatment Of Niemann-Pick Disease Type C1 (Npc1)
05/09/2024 15:26
Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS PRESENTS ENCOURAGING PRELIMINARY SAFETY
DATA
FROM ONGOING PIVOTAL PHASE 3 STUDY AND SUBSTUDY FOR THE
TREATMENT OF NIEMANN-PICK DISEASE TYPE C1 (NPC1)
* CYCLO THERAPEUTICS: TRAPPSOL CYCLO™ DEMONSTRATED TO BE
WELL
TOLERATED IN ONGOING SUBSTUDY WITH SAFETY PROFILE CONSISTENT
WITH THAT OF COMPLETED PHASES
Source text for Eikon: ID:nBw1Ptfz3a
Further company coverage: CYTH.O
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug